Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 6 syntheses or guidelines pooled it.

1. Calcium channel blockers versus other classes of drugs for hypertension.The Cochrane database of systematic reviews · 2022
   Pooled it
2. Calcium channel blockers versus other classes of drugs for hypertension.The Cochrane database of systematic reviews · 2021
   Pooled it
3. First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.Journal of human hypertension · 2018
   Pooled it
4. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.BMJ (Clinical research ed.) · 2016
   Pooled it
5. Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy.The Canadian journal of cardiology · 2008
   Pooled it
6. The role of calcium antagonists in stroke prevention.Journal of clinical hypertension (Greenwich, Conn.) · 2005
   Pooled it
7. Blood pressure targets for hypertension in patients with type 2 diabetes.Annals of translational medicine · 2018
   Article
8. Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity.Current hypertension reports · 2002
   Review
9. INVEST: results of combined strategies to control blood pressure.Clinical cardiology · 2001
   Article
10. Lessons learned from prematurely terminated clinical trials.Current hypertension reports · 2001
    Review
11. Premature termination of clinical trials--lessons learned.Journal of clinical hypertension (Greenwich, Conn.)
    Review

Corrections and comments

• Comment on
  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.1998

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as